6.30
+0.6(+10.53%)
Currency In USD
| Previous Close | 5.7 |
| Open | 5.86 |
| Day High | 6.52 |
| Day Low | 5.72 |
| 52-Week High | 6.55 |
| 52-Week Low | 0.73 |
| Volume | 711,356 |
| Average Volume | 355,282 |
| Market Cap | 405.63M |
| PE | -10.68 |
| EPS | -0.59 |
| Moving Average 50 Days | 5.2 |
| Moving Average 200 Days | 3.08 |
| Change | 0.6 |
If you invested $1000 in Galectin Therapeutics Inc. (GALT) 10 years ago, it would be worth $3,281.25 as of December 04, 2025 at a share price of $6.3. Whereas If you bought $1000 worth of Galectin Therapeutics Inc. (GALT) shares 5 years ago, it would be worth $2,241.99 as of December 04, 2025 at a share price of $6.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experience
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
GlobeNewswire Inc.
Oct 20, 2025 12:00 PM GMT
NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 9t
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the